GLRA
SRPT icon

Gerald L. Ray & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Gerald L. Ray & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,150
Closed -$272K – 268
2013
Q2 		$272K Buy
+7,150
New +$256K 0.06% 223

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Gerald L. Ray & Associates's SRPT Position: Q3 2013 in Review

Gerald L. Ray & Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2013, closing a stake of 7,150 shares — an estimated $272K sold.

Gerald L. Ray & Associates first reported a position in SRPT in Q2 2013 and held it in 1 quarter. The position peaked at $272K in Q2 2013. 134 funds tracked by Wall St. Rank hold SRPT as of Q3 2013.

  • Gerald L. Ray & Associates reported no remaining Sarepta Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Gerald L. Ray & Associates sold 7,150 Sarepta Therapeutics shares in Q3 2013, an estimated $272K.
  • Gerald L. Ray & Associates first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 1 quarter.
  • Gerald L. Ray & Associates's Sarepta Therapeutics position peaked at $272K in Q2 2013.
  • 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2013.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2013, filed 5 Nov 2013.